Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Primary Objective • To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-Co...

Full description

Bibliographic Details
Main Authors: Ruanne V. Barnabas, Elizabeth Brown, Anna Bershteyn, R. Scott Miller, Mark Wener, Connie Celum, Anna Wald, Helen Chu, David Wesche, Jared M. Baeten, for the Hydroxychloroquine COVID-19 PEP Study Team
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
protocol
hydroxychloroquine
post-exposure prophylaxis
household contact
Online Access:http://link.springer.com/article/10.1186/s13063-020-04446-4

Internet

http://link.springer.com/article/10.1186/s13063-020-04446-4

Similar Items